HomeCompareEVKIY vs JNJ

EVKIY vs JNJ: Dividend Comparison 2026

EVKIY yields 6.10% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVKIY wins by $741.00 in total portfolio value
10 years
EVKIY
EVKIY
● Live price
6.10%
Share price
$9.84
Annual div
$0.60
5Y div CAGR
1.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,097.62
Full EVKIY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — EVKIY vs JNJ

📍 EVKIY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVKIYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVKIY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVKIY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVKIY
Annual income on $10K today (after 15% tax)
$518.29/yr
After 10yr DRIP, annual income (after tax)
$932.98/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,053.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVKIY + JNJ for your $10,000?

EVKIY: 50%JNJ: 50%
100% JNJ50/50100% EVKIY
Portfolio after 10yr
$30.6K
Annual income
$2,893.51/yr
Blended yield
9.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EVKIY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
2.0
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVKIY buys
0
JNJ buys
0
No recent congressional trades found for EVKIY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVKIYJNJ
Forward yield6.10%2.13%
Annual dividend / share$0.60$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR1.7%28%
Portfolio after 10y$31.0K$30.3K
Annual income after 10y$1,097.62$4,689.40
Total dividends collected$8.5K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: EVKIY vs JNJ ($10,000, DRIP)

YearEVKIY PortfolioEVKIY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,320$620.12$10,592$272.30+$728.00EVKIY
2$12,780$667.21$11,289$357.73+$1.5KEVKIY
3$14,390$715.94$12,123$472.89+$2.3KEVKIY
4$16,164$766.23$13,141$629.86+$3.0KEVKIY
5$18,113$818.03$14,408$846.81+$3.7KEVKIY
6$20,253$871.29$16,021$1,151.60+$4.2KEVKIY
7$22,596$925.93$18,122$1,588.22+$4.5KEVKIY
8$25,160$981.91$20,930$2,228.20+$4.2KEVKIY
9$27,960$1,039.16$24,792$3,191.91+$3.2KEVKIY
10$31,015$1,097.62$30,274$4,689.40+$741.00EVKIY

EVKIY vs JNJ: Complete Analysis 2026

EVKIYStock

Evonik Industries AG engages in the specialty chemicals business. It operates through Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure segments. The Specialty Additives segment provides polyurethane additives, organically modified silicones, isophorones, epoxy curing agents, oil additives, fumed silicas, matting agents, TAA and TAA derivatives, and acetylenic diol-based surfactants for consumer goods and specialized industrial applications. The Nutrition & Care segment offers amphoteric surfactants, ceramides, phytosphingosines, oleochemicals, quaternary derivatives, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, animal nutrition, and healthcare products. The Smart Materials segment provides hydrogen peroxide, peracetic acid, activated nickel catalysts, precious metal powder catalysts, oil and fat hydrogenation catalysts, amorphous polyalphaolefins, polybutadienes, polyester resins, thermoplastic and reactive methacrylate resins, PEEK, polyamide 12, organosilanes, chlorosilanes, fumed silicas, fumed metal oxides, and precipitated silicas for the automotive, paints, coatings, adhesives, construction, and various other sectors. The Performance Materials segment produces polymer materials and intermediates, including butene-1, DINP, isononanol, cyanuric chloride, alkoxides, and superabsorbent for rubber, plastics, and automotive industries. The Technology & Infrastructure segment provides site management, utilities and waste management, technical, process technology, engineering, and logistics services. It operates in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. The company was founded in 1873 and is headquartered in Essen, Germany. Evonik Industries AG is a subsidiary of RAG-Stiftung.

Full EVKIY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EVKIY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVKIY vs SCHDEVKIY vs JEPIEVKIY vs OEVKIY vs KOEVKIY vs MAINEVKIY vs ABBVEVKIY vs MRKEVKIY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.